Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PTIX

Protagenic Therapeutics Inc

Dec 13 • 04:00PM ET

0.4950

Dollar change -0.0200
Percentage change -3.88	%

Healthcare • Biotechnology • USA • NASD

Peers: ACAD AXSM BTAI SAGE CORT ITCI VNDA NERV SCPH VKTX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.27	Insider Own	14.31%	Shs Outstand	6.79M	Perf Week	-8.33%
Market Cap	3.23M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	5.82M	Perf Month	-23.85%
Income	-5.65M	PEG	-	EPS next Q	-	Inst Own	5.96%	Short Float	1.69%	Perf Quarter	-38.13%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	1.32%	Short Ratio	0.54	Perf Half Y	-46.60%
Book/sh	0.15	P/B	3.31	EPS next Y	-	ROA	-162.74%	Short Interest	0.10M	Perf Year	-43.11%
Cash/sh	0.16	P/C	3.05	EPS next 5Y	-	ROE	-231.87%	52W Range	0.45 - 1.87	Perf YTD	-50.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.91%	ROI	-785.50%	52W High	-73.53%	Beta	-
Dividend TTM	-	Quick Ratio	1.80	Sales past 5Y	0.00%	Gross Margin	-	52W Low	9.63%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	1.80	EPS Y/Y TTM	-40.51%	Oper. Margin	-	RSI (14)	41.50	Volatility	7.83% 15.58%
Employees	3	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	16.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	56.12%	Payout	-	Rel Volume	0.15	Prev Close	0.51
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	182.14K	Price	0.50
SMA20	-13.47%	SMA50	-17.52%	SMA200	-46.65%	Trades		Volume	27,173	Change	-3.88%

Nov-05-24 08:12AM	Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million (ACCESSWIRE)
Oct-29-24 10:27AM	Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million (ACCESSWIRE) +13.73%
Jun-25-24 06:53AM	PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024 (InvestorPlace) +8.46%
May-22-24 08:12AM	Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders (ACCESSWIRE) +12.60%
May-01-24 08:38AM	Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial (ACCESSWIRE) -5.58%
08:42AM	Loading…
Apr-17-24 08:42AM	Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit (ACCESSWIRE)
Apr-01-24 09:53PM	PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023 (InvestorPlace)
04:20PM	Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results (ACCESSWIRE)
Mar-27-24 08:42AM	Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders (ACCESSWIRE)
Mar-25-24 05:00PM	Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call (ACCESSWIRE) +12.37%
Mar-21-24 08:41AM	Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice (ACCESSWIRE) +5.93%
Feb-13-24 08:30AM	Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders (ACCESSWIRE)
Dec-12-23 07:30AM	Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals (ACCESSWIRE) +15.65%
Oct-13-23 09:00AM	Protagenic Therapeutics Announces Date of Annual Shareholder Meeting (ACCESSWIRE) +13.49%
Sep-26-23 08:18AM	Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114 (ACCESSWIRE)
12:55PM	Loading…
Mar-22-23 12:55PM	Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split (ACCESSWIRE) +20.97%
Apr-26-22 08:15AM	Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th (ACCESSWIRE) -5.75%
Nov-16-21 09:58AM	Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update (GlobeNewswire)
Aug-30-21 09:15AM	Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET (GlobeNewswire)
Aug-17-21 07:45AM	Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update (GlobeNewswire)
Jul-23-21 04:21PM	Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial (GlobeNewswire) -9.35%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) +8.75%
Jul-06-21 06:17AM	Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET (GlobeNewswire)
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) +10.47%
Jun-16-21 09:15AM	Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th (GlobeNewswire)
Apr-29-21 03:06PM	Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq (GlobeNewswire) +5.36%
Apr-26-21 08:58PM	Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering (GlobeNewswire) -24.29% -39.62%
Dec-16-20 09:15AM	Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial (GlobeNewswire)
Sep-08-20 12:10PM	Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing (GlobeNewswire)

Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTIX

Protagenic Therapeutics Inc

Upgrade your FINVIZ experience